MTCH,Match Group, Inc. | Communication Services

MTCH

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Match Group, Inc.MTCH

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Match Group, Inc. provides dating products worldwide.

The company's portfolio of brands includes Tinder, Match, The League, Azar, Meetic, OkCupid, Hinge, Pairs, PlentyOfFish, and Hakuna, as well as a various other brands.

The company was incorporated in 1986 and is based in Dallas, Texas.

Latest News >

European Wax Center Names David Berg CEO

Aug 14, 2024

09:20 AM EDT, 08/14/2024 (MT Newswires) -- European Wax Center ( EWCZ ) said Wednesday that the board named David Berg its chief executive, succeeding David Willis. The company said Berg, whose appointment took effect Monday, will also continue serving as its executive chairman. Berg previously served as the company's CEO from 2018 to 2023, European Wax Center ( EWCZ...

What 5 Analyst Ratings Have To Say About Cipher Mining

Aug 14, 2024

Throughout the last three months, 5 analysts have evaluated Cipher Mining ( CIFR ) , offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings...

BRIEF-Wiz Labors To Hire A CFO, Making An IPO Before 2026 Unlikely- The Information

Aug 14, 2024

Aug 14 (Reuters) - * WIZ LABORS TO HIRE A CFO, MAKING AN IPO BEFORE 2026 UNLIKELY- THE INFORMATION Source: https://tinyurl.com/3vt7kjm4 ...

Why Is Cancer-Focused Penny Stock Viracta Therapeutics Trading Higher On Wednesday?

Aug 14, 2024

Wednesday, Viracta Therapeutics Inc. ( VIRX ) stock is trading higher after the company reported Phase 2 NAVAL-1 trial results from Stages 1 and 2 of the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort. Twenty-one patients with primarily Stage III-IV disease received nanatinostat in combination with valganciclovir. As of the June 28 data cutoff, combined...